Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Exp Neurol. 2016 Mar 22;283(Pt B):531–540. doi: 10.1016/j.expneurol.2016.02.023

Figure 1.

Figure 1

This figure presents the structure of the review. First the review indicates roles of the growth factors FGF2, IGF-I, PDGF, CNTF and BDNF on demyelination and remyelination in MS and MS models. It then details therapeutic approaches that are being used to manipulate levels of these factors within the brain and possibly impact demyelinating disease.